# Petros Pharmaceuticals Inc. (PTPI)

Source: https://www.quantisnow.com/company/PTPI
Generated: 2026-11-19T01:47:28.586Z

- Ticker: PTPI
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001815903
- Website: petrospharma.com

## About

Petros Pharmaceuticals, Inc. engages in identifying, acquiring, developing, and commercializing therapeutics for men's health issues in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company develops H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. It also offers prescription medication, such as Stendra for the treatment of male erectile dysfunction; and vacuum erection devices. Petros Pharmaceuticals, Inc. is based in New York, New York.

## Latest PTPI news and filings

- 2026-09-30 21:09 UTC [SEC Form 8-K] [Petros Pharmaceuticals Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Leadership Update](https://www.quantisnow.com/insight/petros-pharmaceuticals-inc-filed-sec-form-8-k-bankruptcy-or-receivership-6730934)
- 2026-08-13 20:33 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Petros Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-petros-pharmaceuticals-inc-6680950)
- 2026-06-25 21:00 UTC [SEC Form 3] [New insider Weinstein Robert claimed ownership of 636,004 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-weinstein-robert-claimed-ownership-of-636004-shares-sec-6616207)
- 2026-06-18 21:14 UTC [SEC Form 8-K] [Petros Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/petros-pharmaceuticals-inc-filed-sec-form-8-k-leadership-update-financial-6609376)
- 2026-06-08 21:00 UTC [SEC Form 4] [Director Walker Wayne Remell was granted 375,000 shares, increasing direct ownership by 74% to 881,333 units (SEC Form 4)](https://www.quantisnow.com/insight/director-walker-wayne-remell-was-granted-375000-shares-increasing-direct-6593832)
- 2026-06-05 21:25 UTC [SEC Form 4] [Officer Boctor Fady was granted 375,000 shares, increasing direct ownership by 72% to 894,986 units (SEC Form 4)](https://www.quantisnow.com/insight/officer-boctor-fady-was-granted-375000-shares-increasing-direct-ownership-6591963)
- 2026-06-05 21:12 UTC [SEC Form 4] [Director Bernstein Bruce was granted 1,875,000 shares, increasing direct ownership by 99% to 3,762,334 units (SEC Form 4)](https://www.quantisnow.com/insight/director-bernstein-bruce-was-granted-1875000-shares-increasing-direct-ownership-6591908)
- 2026-06-05 21:12 UTC [SEC Form 4] [Director Silverman Joshua was granted 4,375,000 shares, increasing direct ownership by 99% to 8,790,450 units (SEC Form 4)](https://www.quantisnow.com/insight/director-silverman-joshua-was-granted-4375000-shares-increasing-direct-ownership-6591903)
- 2026-06-05 21:00 UTC [SEC Form 8-K] [Petros Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/petros-pharmaceuticals-inc-filed-sec-form-8-k-leadership-update-6591820)
- 2026-05-13 21:02 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Petros Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-petros-pharmaceuticals-inc-6551559)
- 2026-04-15 20:30 UTC [SEC Form 10-K] [SEC Form 10-K filed by Petros Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-petros-pharmaceuticals-inc-6501440)
- 2026-03-31 20:30 UTC [SEC Form NT 10-K filed by Petros Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-nt-10-k-filed-by-petros-pharmaceuticals-inc-6479511)
- 2026-02-17 15:50 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Petros Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-petros-pharmaceuticals-inc-6395112)
- 2026-01-06 22:30 UTC [SEC Form 4] [Officer Boctor Fady was granted 500,000 shares, increasing direct ownership by 2,502% to 519,986 units (SEC Form 4)](https://www.quantisnow.com/insight/officer-boctor-fady-was-granted-500000-shares-increasing-direct-ownership-6339332)
- 2026-01-02 22:00 UTC [SEC Form 4] [Director Silverman Joshua was granted 4,375,000 shares, increasing direct ownership by 10,816% to 4,415,450 units (SEC Form 4)](https://www.quantisnow.com/insight/director-silverman-joshua-was-granted-4375000-shares-increasing-direct-ownership-6332542)
- 2026-01-02 22:00 UTC [SEC Form 4] [Director Walker Wayne Remell was granted 500,000 shares, increasing direct ownership by 7,895% to 506,333 units (SEC Form 4)](https://www.quantisnow.com/insight/director-walker-wayne-remell-was-granted-500000-shares-increasing-direct-6332539)
- 2026-01-02 22:00 UTC [SEC Form 8-K] [Petros Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/petros-pharmaceuticals-inc-filed-sec-form-8-k-leadership-update-6332537)
- 2026-01-02 22:00 UTC [SEC Form 4] [Director Bernstein Bruce was granted 1,875,000 shares, increasing direct ownership by 15,202% to 1,887,334 units (SEC Form 4)](https://www.quantisnow.com/insight/director-bernstein-bruce-was-granted-1875000-shares-increasing-direct-ownership-6332524)
- 2025-11-20 19:51 UTC [SEC Form 25-NSE filed by Petros Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-petros-pharmaceuticals-inc-6288560)
- 2025-11-13 21:19 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Petros Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-petros-pharmaceuticals-inc-6277724)
- 2025-11-07 22:00 UTC [SEC Form 8-K] [Petros Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/petros-pharmaceuticals-inc-filed-sec-form-8-k-notice-of-delisting-6268733)
- 2025-09-05 21:00 UTC [SEC Form 8-K] [Petros Pharmaceuticals Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits](https://www.quantisnow.com/insight/petros-pharmaceuticals-inc-filed-sec-form-8-k-changes-in-registrants-6191993)
- 2025-08-15 12:00 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Petros Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-petros-pharmaceuticals-inc-6167788)
- 2025-08-14 20:08 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Petros Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-petros-pharmaceuticals-inc-6166133)
- 2025-06-25 13:15 UTC [Market Insight] [Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity Position](https://www.quantisnow.com/insight/petros-pharmaceuticals-announces-deconsolidation-of-metuchen-pharmaceuticals-subsidiary-strengthening-its-6098534)
- 2025-06-20 21:20 UTC [SEC Form 8-K] [Petros Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/petros-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-6094345)
- 2025-05-21 13:00 UTC [Market Insight] [Petros Pharmaceuticals Announces Transition from NASDAQ to OTC Markets](https://www.quantisnow.com/insight/petros-pharmaceuticals-announces-transition-from-nasdaq-to-otc-markets-6051867)
- 2025-05-21 13:00 UTC [SEC Form 8-K] [Petros Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/petros-pharmaceuticals-inc-filed-sec-form-8-k-notice-of-delisting-6051857)
- 2025-05-20 13:15 UTC [Market Insight] [Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device Developer](https://www.quantisnow.com/insight/petros-pharmaceuticals-partners-with-innolitics-a-leading-software-as-a-medical-device-developer-6049735)
- 2025-05-15 21:22 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Petros Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-petros-pharmaceuticals-inc-6043721)
- 2025-05-15 14:15 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Petros Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-petros-pharmaceuticals-inc-6041260)
- 2025-05-06 13:20 UTC [Market Insight] [Petros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI Platform](https://www.quantisnow.com/insight/petros-pharmaceuticals-strengthens-partnership-with-market-leading-big-data-provider-6020180)
- 2025-05-02 21:25 UTC [SEC Form 8-K] [Petros Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/petros-pharmaceuticals-inc-filed-sec-form-8-k-notice-of-delisting-6016459)
- 2025-05-01 13:20 UTC [Market Insight] [Petros Pharmaceuticals Developing First-in-Industry SaaS Platform Utilizing AI and Electronic Health Records Intended to Facilitate Rx-OTC Switches](https://www.quantisnow.com/insight/petros-pharmaceuticals-developing-first-in-industry-saas-platform-utilizing-ai-and-electronic-6012580)
- 2025-04-29 13:20 UTC [Market Insight] [Petros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification Reforms](https://www.quantisnow.com/insight/petros-proprietary-technology-platform-aligns-with-april-15-2025-president-6006473)
- 2025-04-11 21:22 UTC [SEC Form 8-K] [Petros Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/petros-pharmaceuticals-inc-filed-sec-form-8-k-notice-of-delisting-5985786)
- 2025-04-09 20:05 UTC [SEC Form 8-K] [Petros Pharmaceuticals Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits](https://www.quantisnow.com/insight/petros-pharmaceuticals-inc-filed-sec-form-8-k-changes-in-registrants-5982779)
- 2025-03-31 20:29 UTC [SEC Form 10-K] [SEC Form 10-K filed by Petros Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-petros-pharmaceuticals-inc-5967362)
- 2025-03-20 13:15 UTC [Market Insight] [Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications](https://www.quantisnow.com/insight/petros-pharmaceuticals-to-partner-with-renowned-big-data-provider-to-5953785)
- 2025-03-18 21:00 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Petros Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-petros-pharmaceuticals-inc-5950350)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/PTPI
- Earnings history: https://www.quantisnow.com/earnings/PTPI
- Dividend history: https://www.quantisnow.com/dividends/PTPI
- Insider transactions: https://www.quantisnow.com/insiders/PTPI
- Options chain: https://www.quantisnow.com/options/PTPI
- SEC 8-K filings only: https://www.quantisnow.com/company/PTPI/8-k
- RSS and alerts for PTPI: https://www.quantisnow.com/docs/rss-feeds.md
